EMA Verdict Due On Vertex/CRISPR’s Gene Editing Therapy & Reata’s Omaveloxolone

The European Medicines Agency’s human medicines committee is meeting to decide whether to recommend the pan-EU approval of eight new medicines, including the CRISPR/Cas9 genome-edited cell therapy, exa-cel.

Crispr-cas9 biotechnology dna gene engineering and manipulation. Modern Innovative Healthcare. Crispr cas.
Exa-Cel is made specifically for each patient, using their edited blood stem cells • Source: Shutterstock

Vertex Pharmaceuticals/CRISPR Therapeutics’ cell-based gene therapy exagamglogene autotemcel (exa-cel) and Reata Pharmaceuticals’ omaveloxolone are among the latest drugs on which the European Medicines Agency is due to decide this week whether they should be granted EU-wide marketing approval.

Exa-cel is a CRISPR/Cas9 genome-edited cell therapy indicated for the treatment of the genetic conditions, sickle cell disease (SCD) and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography